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Abstract– The number of diabetic people is 
constantly growing across the globe including 
Hungary. According to the WHO diabetes is a future 
endemic problem. Beside the social problems, diabetes 
causes a serious economic impact as well; hence, it is 
important to draw attention on it together with its 
impacts. The paper discusses about this question, 
introducing the types of diabetes, its indicators, 
complications (mostly concentrating on type II 
diabetes), and also its treatments and prevention. 
Investigation of the changes in diabetic population and 
also the burden of this disease both in domestic and 
global levels are discussed as well. 
Keywords—prevalence; diabetes mellitus; health 
expenditure 
I. INTRODUCTION 
In the recent decades and years the world has become 
more and more developed. At the same time, people have 
become lazier, and show a tendency to live unhealthier, 
neglecting physical activity, regular meals, etc. As a 
result, obesity, inadequate blood pressure, reduced 
glucose tolerance level, or even high insulin level 
probability increased as a direct indicators of metabolic 
syndromes. These syndromes also carry the risk of 
several diseases, including diabetes mellitus. The number 
of people with diagnosed diabetes (and with undiagnosed 
diabetes too) is constantly growing across the globe, 
including Hungary. Due to this reason the World Health 
Organization considers the disease as an endemic 
problem to the world [11]. 
As a result, it is very important to draw attention on 
diabetes, and its types, indicators, complications (mostly 
concentrating on type II diabetes / non-insulin dependent 
diabetes / adult diabetes), but about the treatment and 
prevention possibilities as well. However, as the disease 
has a global impact on the society, it is worth examining 
the changes of diabetic population on other sectors as 
well, including economic factors. The scope of this paper 
tries to give a short review on this latter aspect, trying to 
focus both on domestic and global levels, since the 
negative effects of diabetes damage not only the lifestyle 
of a patient, but also generate an additional expenditure 
of the treatments both for the society and for the national 
economy. 
The paper is structured as follows: first a review on 
diabetes is presented, than the prevalence of the disease. 
This is followed by the burden of the disease taking into 
account the economic factors. Finally a short summary 
concludes the paper. 
II. DIABETES 
A. Formations and Symptoms of diabetes 
The body’s primary energy resource is glucose. For 
this fuel the body disassembles the intake carbohydrate 
coming for the meals taken. The glucose (sugar) comes to 
the veins to ensure the proper functioning of the body. 
The amount of glucose given to cells in a healthy 
person is regulated by insulin. The pancreas is 
responsible for the production of this hormone. The 
required amount of this hormone is automatically 
controlled by the pancreas after a meal. Hence, if the 
glucose level is too high in the blood it can be concluded 
that the pancreas does not work well so the produced 
insulin amount is not enough, or the cells cannot react in 
the right way to the insulin. As a result, the body is 
damaged to receive its primary source of energy [6], [7]. 
Consequently, the main reason for diabetes is the 
total or partial absence of insulin. The clinical symptoms 
of this disease are [6]: 
• frequent urination; 
• polydipsia (continuous thirst feeling); 
• rapid weight loss that cannot be explained; 
• visual disturbances; 
• infection that is difficult to heal and often 
recurrent; 
• diabetic ketoacidosis. 
B. Types of diabetes 
According to the World Health Organization diabetes 
mellitus has three primary types [7], [8]: 
• type I diabetes; 
• type II diabetes; 
• gestational diabetes (during pregnancy). 
 
1) Type I diabetes 
Type I diabetes is caused by the destruction of the 
beta-cells that produce insulin within the pancreas. 
Because of this, insulin injected from outside of the body 
is essential, as if the patient does not receive it, 
ketoacidosis may occur leading to coma, the outcome of 
which could result in the death of the patient. That's why 
type I is known as insulin-dependent diabetes as well. 
Usually the symptoms occur before the age of 30. It is 
also important to note that diabetes type cannot be 
determined just by age. 
The insulin-dependent diabetes has two subtypes. 
One of them is the 1A autoimmune mechanisms type and 
the other is the 1B idiopathic type. 
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In 1A subtype diabetes occurs by the reaction of the 
T-cell autoimmune mechanism that (it is a type of white 
blood cell) destroys the beta-cells. In the adult ages, type 
I diabetes can evolve as well, referred to LADA (Latent 
Autoimmune Diabetes in Adults) and it is easy to confuse 
with type II diabetes. 
In 1B subtype the doctors cannot identify the cause 
of the loss of beta cells and an autoimmune process 
cannot be detected either. 
2) Type II diabetes 
In this type, the main reason of diabetes is the slowly 
developing insulin resistance (the insulin is in the body, 
but that cannot utilize it in the required amount) and the 
devastation of the beta-cells (necessary for insulin 
production). This type occurs most commonly in the adult 
population, but nowadays the disease appears more and 
more popular among the young generation. This type has 
a latent nature, so before evolving there are no clinical 
symptoms. It is mostly caused by the incorrect / 
unhealthy lifestyle (both inadequate nutrition and lack of 
physical activity). Type II diabetes is known as non-
insulin dependent diabetes or adult diabetes as well, as in 
its early stages it does not need external insulin dosage to 
survive. 
3) Gestational diabetes 
This is the type of diabetes that was discovered 
during pregnancy or begins during pregnancy, and 
includes reduced glucose tolerance of the pregnant 
women. 
Since diabetes may have been formed before 
pregnancy, the diagnosed young mothers may suffer from 
type I or type II diabetes. The first test should be carried 
out between the 24-28 weeks and the second test should 
take after the sixth week of giving birth. 
C. Indicators of diabetes [1], [3], [4] 
The main indicators of diabetes are blood and urine. 
By measuring these it is easy to detect diabetes using 
regular monitoring even if there is a beginning disorder in 
carbohydrate metabolism. 
One can rightly ask when it is worth looking at the 
blood or urine glucose level of the patient. The 
measurements can be done in home environment; blood 
glucose testing provides a more comprehensive picture of 
self-testing than urinary glucose testing. However, by 
finger-tip measurements it is not possible to obtain 
accurate information about how much deviation differs 
from the normal value threshold; this measurement is just 
good to give a rough control of the patient in case. 
Other control ways can be signs of diabetes as well: 
great weight loss with average or high appetite, persistent 
feeling of thirst with many fluids, visual disturbances, or 
occasional numbness of the fingers, and, in a drastic case 
consciousness or coma. However, the examination of 
asymptomatic persons is also justified in the following 
cases: 
• diabetic patients diagnosed in the individual's 
family; 
• obesity; 
• cardiovascular diseases; 
• high blood pressure (hypertension); 
• high blood lipid levels (hyperlipidaemia). 
In the case of asymptomatic people, no far-reaching 
conclusions can be drawn, even if the standard deviation 
is high. In such cases it is necessary to do other 
measurement as well at other times including glucose 
tolerance test. 
Another important indicator of diabetes is the 
measurement of HbA1C (glycated hemoglobin). This is a 
long-term indicator. Blood glucose measurement is not 
triggered by HbA1C measuring as HbA1C is only 
measured every 2-3 months. By measuring glycated 
hemoglobin it is able to better determine how successful 
the treatment is or if there are problems to comply the 
prescribed diet by its doctor. 
Measurement of HbA1C measures the hemoglobin-
related (glycated) sugar that transmits the color of red 
blood cells in the blood. The time of this process gives a 
picture of it during the last 2-3 months, so this type of 
study should be done only in such intervals. That is, the 
higher the patient's blood sugar level, the more sugar will 
bind to the hemoglobin. A healthy individual has a 
HbA1C of less than 7% (usually between 4-6%), while 
the main goal for diabetic patients is to get their level 
closer to 7%. It is important to achieve this value because 
the higher the proportion –as far time is moving forward– 
the chance to occur complication by diabetes is highly 
increased. 
D. Serious complications of diabetes [2], [3], [7] 
Any type of diabetes can develop complications –
both acute and chronic– that spoil the patient's lifestyle. 
For this proper medication is required (causing a direct 
effect on the costs of the disease and globally on the 
economy). It is important to note that the risk of 
complications and its costs, together with the treatment 
costs are also dependent on the progression of diabetes. 
Two types of complications can be distinguished, 
acute and chronic. 
1) Acute 
We spoke about acute complication when it develops 
shortly or it is fast moving. Acute complications can 
develop with diabetes. Such complications are 
hypoglycaemia (low level of blood glucose) and 
hyperglycemia (high level of blood glucose). Both 
complications are life-threatening, as if the patient does 
not get the proper care, it could be lead to their deaths. 
2) Chronic 
We spoke about chronic complication when it 
develops slowly or stands for a long period of time. The 
more frequent chronic complications of diabetes can be 
divided into two major groups. One is the 
microangiopathic group that is characterized by its name 
(vessel diameter < 500 µm), and is characterized by 
complications due to the vascular damage. This group 
includes, among other things, the following degradations: 
• eye (retinopathy); 
• kidney (nepropathia); 
• nerve (neuropathy). 
The other group of chronic complications is the 
known as the macroangiopathic group characterized by 
cardiovascular damage. 
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E. Treatment and prevention [3], [6], [7] 
A diabetic patient's care is determined by two 
components: the type of diabetes and the occurrence of 
complications. However, the treatment itself is based on 
four main pillars: 
• diet; 
• physical activity; 
• oral medication; 
• insulin therapy. 
The types of treatments are divided into two main 
groups according to whether they are non-medication or 
medication based ones. At first, the proper diet and 
physical activity plays the most important role. These are 
influencing the non-medication treatment of diabetes as 
well as in case of preventing diabetes (especially in case 
of type II diabetes). 
In case of medication treatment or insulin injection 
lower blood glucose and other anti-diabetes medications 
are in the focus. These compositions are in the A10 (A = 
Gut and Metabolic, 10 = Antidiabetic Therapy) 
classification system within the ATC classification 
system (meaning anatomical, therapeutic and chemical 
classification system). Insulin based medications are 
classified in group A10A, while blood glucose lowering 
in A10B. The oral medication treatment is intended to 
reduce insulin resistance, increase insulin secretion 
(control blood glucose levels) or slow down the 
absorption of carbohydrate from the intestine. For insulin 
treatment, the primary design aspect is to determine the 
adequate amounts of insulin throughout the day, taking 
into account the patient’s daily rhythm. Two types of 
insulin are distinguished (human-traditional and 
analogue-modern), and the correct choice for the 
treatment is determined by the physician. 
III. PREVALENCE OF DIABETES 
A. Global prevalence of diabetes 
During investigation the age group of 20-79 has been 
taken into account, as the onset of type II diabetes (the 
90-95% of the overall diabetes population) is the most 
significant within this age range. The Diabetes Atlas 
published by the International Diabetes Federation (IDF) 
[10], says that the amount of people affected by 2040 –if 
the condition incidence remains the same– could be over 
642 million individuals within the 20-79 age group. At 
that time the predicted population of the planet will be a 
around 9.1 billion; hence, today’s 5.6% diabetic 
population of the World’s is estimated to increase to 7% 
by 2040. Further investigating this prediction, the 20-79 
age group –being 64% of the overall mankind– remains 
constant; hence, in 2040 the estimated prevalence within 
this group will raise to 11% from 8.8% measured in 2015. 
The population growth will increase the amount of 
affected people as well. 
Consequently, if the prevalence rises up to 11%, then 
it can be declared that diabetes becomes globally 
endemic. Obviously, this is an estimated amount, as the 
fluctuation of the population cannot be predicted 
numerically; hence, the number of people affected by 
diabetes is unpredictable. Figure 1 shows the incidence 
between 2013 and 2015, within the 20-79 age group (in 
million). 
 
Fig. 1: The rate of the non diabetic and diabetic in the 20-79 years 
population 
B. Domestic prevalence of diabetes 
According to the statistics of IDF [10], the amount of 
individuals diagnosed with diabetes was constantly 
decreasing, but then from 2014 to 2015 there was a 
significant increase. The result is the change of 
prevalence level from 7.5% to 9.3%. The subsidence here 
does not mean that the occurring of diabetes has dropped, 
but the number of individuals diagnosed with it has been 
decreased as a result of mortality. The exact number of 
patients cannot be determined only estimated, mostly dut 
to the unknown exact number of type II is population 
(even nationally many individuals don't even know their 
condition – according to few sources, an estimated 
population of 1 million people is “latent” diabetes in 
Hungary). The increase by leaps and bounds is 
attributable to the more frequent medical examinations, 
or, in many cases, even the occurring of lifestyle issues 
caused by the complications of the condition, which led 
to discover and register it. The fluctuation of prevalence 
in Hungary can be observed on the Figure 2, within the 
20-79 age group (in thousands). 
 
 
Fig. 2: The rate of the non diabetic and diabetic in the domestic 20-79 
years population 
IV. THE BURDEN OF DIABETES 
The burden of the disease can be divided into two 
major roles. One of them is the healthcare expenditure –
about 70% of total costs–, while another is the indirect 
costs –about 30% of total costs. A few examples of health 
expenditures: 
• Institutional care (hospital or home); 
• Outpatient care (medical treatment, 
emergency care, hospital outpatient care and 
home or hospice care); 
• Medicines (tablets, insulin and their devices). 
Indirect costs can be categorized as follows: 
• Number of work days lost; 
• Limited work; 
• Continuous disability; 
• Mortality. 
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As the treatment of diabetes depends on the time 
discovered, the treatment costs are variable. It is therefore 
desirable to perform screening tests to detect the disease 
as soon as possible. Hence, the costs of both medicines 
and treatments can be reduced as well together with the 
health expenditures (because the complications generate 
them mainly). 
A. Global 
Regarding global level costs, this has a direct 
influence on Hungarian tendencies. In the world, diabetes 
caused expenses increase every year. In 2013 the total 
cost was 548,5 billion USD, that number grew to 611,85 
billion USD to 2014 and further, in 2015 to 672,4 billion 
USD. 
In 2015 the North American and Caribbean region 
spent the most to diabetes and its complications (based on 
IDF statistics). Next, the European and the Western 
Pacific region is followed then the South and Central 
America; Middle East and North Africa; South-East Asia 
and finally Africa. Given the global level of total 
spending (672.4 billion USD) it can be observed that 
slightly more than half (51%) of the expenditure belongs 
to the North American and the Caribbean region. Hence, 
at global level, 51% of the total costs were spent on 
10.6% of the total individuals with diabetes. By 
comparison, the region with the largest number of 
patients (Western Pacific) with nearly 36.9% of patients 
from the whole diabetic population accounted only 15.7% 
of the total 2015 diabetes expenditure. 
To illustrate the dimension of global diabetes costs it 
could be mentioned that Hungary's public debt in 2015 
was 80,395 billion EUR, which converted with the 
current exchange rates is equal to 87,739 billion USD. 
Hence, the 2015 global diabetes costs are 7,6 times bigger 
than the whole Hungarian public dept. 
B. Domestic 
According to the statistics of the IDF [10], the 
amount of diabetes related health expense in Hungary 
was 1158 USD/head in 2014, while in 2015 was 1208 
USD/head. In 2014 the Hungarian population was 9 877 
365, and the domestic prevalence was 7,51%. Hence, 
according to the IDF there were 741 790 people with 
diabetes, and that overall costs covered 859 million USD 
(around 250 billion HUF predicted value). By 2015 the 
Hungarian population decreased to 9 855 571 persons, 
and with the 2015's prevalence (9,3%) in Hungary were 
916 568 people with diabetes, with a total expense of 
1107 million USD (around 322 billion HUF). 
It is worth examining the costs changes in the 
treatment with drugs too. Figure 3 shows the financial 
changes (in million HUF) in the insulin type medicals 
during 2012 and 2016. 
According to Figure 3, from the year 2013 the insulin 
type medical expenses constantly grew (insulin type can 
be A10AB -fast-acting insulin- , A10AC -intermediate-
acting insulin-, A10AD -intermediate or long-acting 
combined with fast acting insulin- or A10AE -long-acting 
insulin- ATC code drugs). With blue one can see the 
changes the health insurance costs, dark red reflects the 
changes of medication price, while yellow the costs of 
health care support. From 2013 the gross consumer price 
was grown by 2598 million HUF. 
 
Fig. 3: The financial changes in the insulin type medicals 
 
 
Fig. 4: The insulin type drugs turn overs by price and sold boxes 
Figure 4 shows the summed A10A ATC code drugs 
changes by sold boxes and the gross consumer price in 
million HUF between 2012 and 2016. 
It can be seen that in the monitored time, by the year 
2014 the sold boxes and the gross consumer price started 
to grow constantly (the gross consumer price started the 
increasing tendency by 2013). There was clearly a price 
increase from 2015 to 2016, because the sold boxes are 
nearly equal, but the consumer price has grown by nearly 
700 million HUF.  
This significant increase in the price could be 
triggered by the possible market price increase or by the 
changes in the drugs classification type (96% of the price 
growth was covered by health subsidies, while the 
remaining 28 million HUF was financed by the patients 
themselves). 
Furthermore, the research contained the A10B blood 
glucose lowering drugs financial changes. This ATC code 
contains the A10BA (biguanides), A10BB 
(sulfonylureas), A10BC (sulfonamides), A10BD 
(combination of oral glucose lowering drugs), A10BF 
(alpha-glucosidase inhibitors), A10BG 
(thiazolidinediones), A10BH (dipeptidyl-peptidase-4 
inhibitors) and the A10BX (other blood glucose lowering 
drugs excluding insulin). 
Figure 5 shows the sold boxes (each) and the gross 
consumer price (million HUF) changes during the 2012-
2016 period. 
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Fig. 5: The non-insulin type drugs turn overs by price and sold boxes 
 
 
Fig. 6: The financial changes in the non-insulin type medicals 
 
The number of the sold boxes constantly decreased 
from 2013 until 2015, then by the year 2015 to 2016 the 
sold boxes amount raised up again, nearly above the sold 
quantity in 2012 (in 2012 the number of the sold boxes 
were 6.441.955 each and in 2016 were 6.517.368 each). 
During the examined time the sold amount of boxes were 
always above 6,4 million each (except in 2015); it is a 
huge number in spite of the fact that the sales only 
reached the 2012's numbers. Hereby the gross consumer 
price growth year by year, notwithstanding that the sold 
number of boxes decreased from 2015. Consequently, the 
drugs price in the A10B ATC code also increased during 
the years just like the A10A ATC code drugs’ price. 
Figure 6 shows the financial changes during the 
monitored time (2012-2016) in the A10B ATC coded 
medicines, in million HUF. As one can see, in this type of 
drugs the fee is much bigger and the support by health 
insurance is much smaller than the insulin-typed drugs. 
This resulted due to the fact that the A10B ATC codes 
drugs are less supported by the public sector. 
In summary, it can be declared that the cost 
tendencies constantly grow in both types of medicines 
(A10A and A10B). 
From the public side, during the monitored time the 
support of healthcare has been developed as follows 
(rounded data): in 2012 it was 28 billion HUF, in 2013 it 
cost 28,5 billion HUF, in the year 2014 cost 30,9 billion 
HUF, and in 2015 it growth to 32,6 billion HUF, and for 
2016 the costs increased to 35 billion HUF. 
During this time an additional 7 billion HUF plus 
expenditure appeared at the public level. This extra 
amount of cost was generated by the increased support by 
the public sector with the A10B ATC coded drugs 
(during the monitored time, this type of drug support 
growths by 5 billion HUF, that is nearly 2 times bigger 
than the costs increase in the private sector). It is 
important to notice that the support by healthcare has 
been paid by the affix paying people as well, not only by 
the public sector. 
 
 
From the patient side, the expenditures also increased 
year by year in both types of drugs. The numbers are as 
follows (rounded data included the people with health 
care support): in 2012 it was 6,2 billion HUF, in 2013 it 
cost 6,9 billion HUF, in 2014 it was 7,5 billion HUF, in 
2015 7,9 billion HUF, and in 2016 the private burden 
increased to 8,6 billion HUF for the people with diabetes. 
The fee of the patients grew with a total of 2,4 billion 
HUF in the monitored time (likely in the A10B type 
where the expenditures growth by 2,2 billion HUF while 
in the A10A type drug costs only increased by 200 
million HUF). 
It is important to point out that this type of costs of 
disease is only on the shoulders of the diabetic 
population. At the above-mentioned data the question is 
whether the burden is high for the domestic diabetic 
population, while there is a double burden on patients 
who are actively working.  
Furthermore, the above examined costs do not 
include the expenditures generated by the disease 
complications due to the lack of enough certified data. As 
a result, only the financial changes in the drugs type were 
monitored; however, important amount of cosst occurred 
by the complications in health expenses (e.g. see [5], 
highlighting that the total expenditures for diabetes 
including the cost of complications were 175 billion 
HUF). 
Since diabetes have many complications that can 
seriously affect the lifestyle of a patient, it is also 
important to look at the indirect costs generated by this 
disease (for example, the diabetic foot amputation, stroke 
or heart attack). If the patient experiences the above-
mentioned examples they should be treated by doctors. 
For this reason, the patient is receiving in-patient care for 
a while which occurs in healthcare expenses, but when 
talking about an employee, it is likely that many work 
days will fall out, and even the incapacity of work may 
occur; furthermore, if they fail to treat the patients in 
time, or if other complications occurs, it can also lead to 
the death of the patient. 
Since there is no available database where the 
number of diabetics registered among the active workers 
and the lack of sources on complications, only the cause 
of death has been analyzed. Such costs include, for 
example, the funeral and rental of plots. Naturally, in 
larger cities the costs are higher than in the rural areas. 
Funeral prices are greatly influenced by the needs of 
deceased relatives. According to the data of the Budapest 
Funeral Institute [9], the price of a funeral starts at about 
70 000 HUF and the total amount can be up to 250 000 
HUF – the price does not include the administrative fee 
or the amount charged for the preparation (the latter range 
between 23 000 HUF and 45 000 HUF, while the former 
costs between 7 000 and 22 000 HUF). 
Consequently, it can be stated that mortality is also a 
serious cost for the relatives, as the cost of a burial is 
around 100 000 HUF, but can reach up to 300 000 HUF. 
As the present minimum wage in Hungary is 127 000 
HUF, it is clear that a funeral has serious financial 
implications and can be a serious burden for the family. 
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V. SUMMARY 
At global level, the cost of diabetes increases year by 
year, but it is really interesting that growth in the North 
American and Caribbean region is the largest in the 
period under review of this study, and it also spends the 
most in this region (about 50% of total expenditure), 
while only about 10.6% of patients are located there. The 
costs will increase in a long term because of the latent 
nature of type II diabetes. At global level, the costs 
occurred by diabetes grows year by year (both in the 
private and public sectors) in Hungary too. 
Summing up the tendencies of the recent years in 
Hungary, diabetes mellitus prevalence increases in the 
domestic population and the costs of the disease also 
generates a bigger burden year by year for the economy. 
There is currently no economic solution for reducing this 
burden only the prevention could decrease the costs. 
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